

31.8.2016

To:  
Unit B4 "Medical products – Quality, Safety and Innovation"  
[SANTE-B4-GL-results-laypersons@ec.europa.eu](mailto:SANTE-B4-GL-results-laypersons@ec.europa.eu)  
European Commission  
F101 08/058  
B-1049 Brussels (Belgium)

## Submission of comments on **Summary of Clinical Trials Results for Laypersons** – Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use

### Comments from:

Name of organisation or individual

**EuropaBio - the European Association for Bioindustries**

Avenue de l'Armée 6 | B-1040 Brussels

[www.europabio.org](http://www.europabio.org)

Business association registered in EU Transparency Register.

Identification number in the register: 1298286943-59

Contact: Riccardo Mezzasalma, Healthcare Biotechnology Manager

[r.mezzasalma@europabio.org](mailto:r.mezzasalma@europabio.org)

## 1. General comments

General comment (if any)

EuropaBio welcomes the opportunity to respond to this public consultation, which is touching on a topic of particular interest to our members.

EuropaBio has had sight of the response to this consultation by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and supports the comments submitted by EFPIA.